Hi Hottod, do you have any thoughts on NEU's work with respect to ADHD, and treatment of its particular symptoms? With ADHD regularly occurring with autism (and their symptom overlap) I wondered if any of the behavioural observations or efficacy measures thus far would lead to NEU's compounds being considered for a new line of treatment? Ritalin and others are presently the drugs of choice, but they come with their own set of side effects, particularly emotional/appetite. Do you see any potential for this to be a new path forward down the track for treating ADHD?
Thank you kindly.
Phase 2, page-13
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.10 |
Change
-0.620(2.99%) |
Mkt cap ! $2.569B | |||
| Open | High | Low | Value | Volume |
| $20.41 | $20.45 | $19.92 | $5.947M | 296.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 999 | $20.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.19 | 10 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |